Results 131 to 140 of about 62,751 (282)

Supplementary Material for: H2 Receptor Antagonists versus Proton Pump Inhibitors in Patients on Dual Antiplatelet Therapy for Coronary Artery Disease: A Systematic Review

, 2018
Aws Almufleh, F. Daniel Ramirez, Derek So, M. Le May, Aun‐Yeong Chong, Nazi Torabi, Benjamin Hibbert   +6 more
openalex   +1 more source

Targeted Inhibition of CD74+ Macrophages by Luteolin via CEBPB/P65 Signaling Ameliorates Osteoarthritis Progression

Advanced Science, EarlyView.
This study identifies CD74⁺ macrophages as key drivers of synovial inflammation in osteoarthritis (OA). The flavonoid luteolin is predicted to inhibit this pathway by blocking Nuclear Factor Kappa‐light‐chain‐enhancer of Activated B cells (NF‐κB) signaling. To enhance delivery, a targeted nanoplatform (MDSPL) is developed.
Rui Peng, Bo Yu, Lei Zhang, Zhaowen Xue, Lutian Yao, Qingjun Yang, Zitao Liu, Sizhi Wu, Yongquan Huang, Xiaofei Zheng, Huiying Guo, Songwei Huan, Tao Jiang, Huajun Wang, Yulong Wei, Tao Gui   +15 more
wiley   +1 more source

Multichannel intraluminal impedance (MII) in the evaluation of patients with persistent GERD symptoms despite proton pump inhibitors (PPI): A multicenter study [PDF]

, 2003
Steven S. Shay, Daniel Sifrim, Radu Țuțuian, Xin Zhang, Marcelo F. Vela, Donald O. Castell   +5 more
openalex   +1 more source

The Choice of a Proton Pump Inhibitor [PDF]

Basic & Clinical Pharmacology & Toxicology, 2004
openaire   +2 more sources

Stabilized Ion Selectivity Corrects Activation Drift in Kalium Channelrhodopsins

Advanced Science, EarlyView.
As newly emerged optogenetic tools, potassium channelrhodopsins (KCRs) can drift from inhibition to activation during illumination as K⁺ selectivity declines. It is shown that both the absolute K⁺/Na⁺ permeability ratio and its stability over time govern this drift, identify KCR1‐C29D as a reliably inhibitory variant, and outline design principles for ...
Xiao Duan, Chong Zhang, Stanislav Ott, Zhiyi Zhang, Christiane Ruse, Sven Dannhäuser, Robert Jacobi, Nadine Ehmann, Divya Sachidanandan, Georg Nagel, Manfred Heckmann, Robert J. Kittel, Alexander Gottschalk, Adam Claridge‐Chang, Shiqiang Gao   +14 more
wiley   +1 more source

Study of Acid Catalyzed Reactions of Proton Pump Inhibitors at D.M.E.

, 2007
Hanuman P. Gupta, Kalawati Saini, Priyanka Dhingra, Rajayashree Pandey   +3 more
openalex   +1 more source

ARL3 Enhances ERα Stability via USP10 Deubiquitination to Promote Endocrine Resistance and Drive Mitochondrial Metabolic Reprogramming in HR+ Breast Cancer

Advanced Science, EarlyView.
This study identifies ADP‐ribosylation factor‐like protein 3 (ARL3) as a novel chaperone that stabilizes estrogen receptor α (ERα) in breast cancer. ARL3 promotes tumor growth by recruiting USP10 to remove ubiquitin chains from ERα, preventing its degradation.
Han Li, Yang Liu, Zehao Cai, Kang Li, Shun Gao, Ailin Lan, Dan Shu, Kuan He, Xin Liu, Yang Peng, Shipeng Guo, Haochen Yu, Aishun Jin, Meiying Shen, Shengchun Liu   +14 more
wiley   +1 more source

Mo1843 Mast Cell Densities on Esophageal Mucosal Biopsies Were Higher in Eosinophilic Esophagitis Versus Proton Pump Inhibitor-Responsive Esophageal Eosinophilia in Adults

, 2014
Shikha Mangla, Matthew J. Hamilton, Karen S. Hsu Blatman, Jason L. Hornick, Walter W. Chan   +4 more
openalex   +1 more source

Review article: proton pump inhibitors and bacterial overgrowth [PDF]

, 2005
Craig Williams, Kenneth E.L. McColl
openalex   +1 more source

Evolution of proton pump inhibitor prescribing from 2017 to 2021 at 14 secondary and tertiary hospitals in China：a multicentre cross-sectional study [PDF]

, 2023
Min Zeng, Yuan Li, Tao Chen, Shengmin Zhang, Hongli Luo   +4 more
openalex   +1 more source